Selenium in oncology: from chemistry to clinics.
Identifieur interne : 002A99 ( PubMed/Checkpoint ); précédent : 002A98; suivant : 002B00Selenium in oncology: from chemistry to clinics.
Auteurs : Oliver Micke [Allemagne] ; Lutz Schomburg ; Jens Buentzel ; Klaus Kisters ; Ralph MueckeSource :
- Molecules (Basel, Switzerland) [ 1420-3049 ] ; 2009.
Descripteurs français
- KwdFr :
- MESH :
- métabolisme : Radioprotecteurs, Sélénium.
- traitement médicamenteux : Lymphoedème, Tumeurs.
- usage thérapeutique : Radioprotecteurs, Sélénium.
- Cytoprotection, Essais contrôlés randomisés comme sujet, Humains, Sélénium, Tumeurs.
English descriptors
- KwdEn :
- Cytoprotection, Humans, Lymphedema (drug therapy), Neoplasms (drug therapy), Neoplasms (prevention & control), Radiation-Protective Agents (metabolism), Radiation-Protective Agents (therapeutic use), Randomized Controlled Trials as Topic, Selenium (chemistry), Selenium (metabolism), Selenium (therapeutic use).
- MESH :
- chemical , chemistry : Selenium.
- chemical , metabolism : Radiation-Protective Agents, Selenium.
- drug therapy : Lymphedema, Neoplasms.
- prevention & control : Neoplasms.
- chemical , therapeutic use : Radiation-Protective Agents, Selenium.
- Cytoprotection, Humans, Randomized Controlled Trials as Topic.
Abstract
The essential trace element selenium, which is a crucial cofactor in the most important endogenous antioxidative systems of the human body, is attracting more and more the attention of both laypersons and expert groups. The interest of oncologists mainly focuses in the following clinical aspects: radioprotection of normal tissues, radiosensitizing in malignant tumors, antiedematous effect, prognostic impact of selenium, and effects in primary and secondary cancer prevention. Selenium is a constituent of the small group of selenocysteine-containing selenoproteins and elicits important structural and enzymatic functions. Selenium deficiency has been linked to increased infection risk and adverse mood states. It has been shown to possess cancer-preventive and cytoprotective activities in both animal models and humans. It is well established that Se has a key role in redox regulation and antioxidant function, and hence in membrane integrity, energy metabolism and protection against DNA damage. Recent clinical trials have shown the importance of selenium in clinical oncology. Our own clinical study involving 48 patients suggest that selenium has a positive effect on radiation-associated secondary lymphedema in patients with limb edemas, as well as in the head and neck region, including endolaryngeal edema. Another randomized phase III study of our group was performed to examine the cytoprotective properties of selenium in radiation oncology. The aim was to evaluate whether sodium selenite is able to compensate a preexisting selenium deficiency and to prevent radiation induced diarrhea in adjuvant radiotherapy for pelvic gynecologic malignancies. Through this study, the significant benefits of sodium selenite supplementation with regards to selenium deficiency and radiotherapy induced diarrhea in patients with cervical and uterine cancer has been shown for the first time in a prospective randomized trial. Survival data imply that supplementation with selenium does not interfere with the positive biological effects of radiation treatment and might constitute a valuable adjuvant therapy option especially in marginally supplied individuals. More recently there were emerging concerns coming up from two large clinical prevention trials (NPC, SELECT), that selenium increases the possible risk of developing diabetes type II. Despite obvious flaws of both studies and good counterarguments, a controversial debate remains on the possible advantage and risks of selenium in cancer prevention. However, in the light of the recent clinical trials the potential benefits of selenium supplementation in tumor patients are undeniable, even if further research is needed.
DOI: 10.3390/molecules14103975
PubMed: 19924043
Affiliations:
Links toward previous steps (curation, corpus...)
Links to Exploration step
pubmed:19924043Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Selenium in oncology: from chemistry to clinics.</title>
<author><name sortKey="Micke, Oliver" sort="Micke, Oliver" uniqKey="Micke O" first="Oliver" last="Micke">Oliver Micke</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Radiotherapy and Radiation Oncology, Franziskus Hospital, Kiskerstrasse 26, D- 33615 Bielefeld, Germany.</nlm:affiliation>
<country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Department of Radiotherapy and Radiation Oncology, Franziskus Hospital, Kiskerstrasse 26, D- 33615 Bielefeld</wicri:regionArea>
<wicri:noRegion>33615 Bielefeld</wicri:noRegion>
<wicri:noRegion>33615 Bielefeld</wicri:noRegion>
<wicri:noRegion>D- 33615 Bielefeld</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Schomburg, Lutz" sort="Schomburg, Lutz" uniqKey="Schomburg L" first="Lutz" last="Schomburg">Lutz Schomburg</name>
</author>
<author><name sortKey="Buentzel, Jens" sort="Buentzel, Jens" uniqKey="Buentzel J" first="Jens" last="Buentzel">Jens Buentzel</name>
</author>
<author><name sortKey="Kisters, Klaus" sort="Kisters, Klaus" uniqKey="Kisters K" first="Klaus" last="Kisters">Klaus Kisters</name>
</author>
<author><name sortKey="Muecke, Ralph" sort="Muecke, Ralph" uniqKey="Muecke R" first="Ralph" last="Muecke">Ralph Muecke</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2009">2009</date>
<idno type="RBID">pubmed:19924043</idno>
<idno type="pmid">19924043</idno>
<idno type="doi">10.3390/molecules14103975</idno>
<idno type="wicri:Area/PubMed/Corpus">002C75</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">002C75</idno>
<idno type="wicri:Area/PubMed/Curation">002C75</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">002C75</idno>
<idno type="wicri:Area/PubMed/Checkpoint">002C75</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">002C75</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Selenium in oncology: from chemistry to clinics.</title>
<author><name sortKey="Micke, Oliver" sort="Micke, Oliver" uniqKey="Micke O" first="Oliver" last="Micke">Oliver Micke</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Radiotherapy and Radiation Oncology, Franziskus Hospital, Kiskerstrasse 26, D- 33615 Bielefeld, Germany.</nlm:affiliation>
<country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Department of Radiotherapy and Radiation Oncology, Franziskus Hospital, Kiskerstrasse 26, D- 33615 Bielefeld</wicri:regionArea>
<wicri:noRegion>33615 Bielefeld</wicri:noRegion>
<wicri:noRegion>33615 Bielefeld</wicri:noRegion>
<wicri:noRegion>D- 33615 Bielefeld</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Schomburg, Lutz" sort="Schomburg, Lutz" uniqKey="Schomburg L" first="Lutz" last="Schomburg">Lutz Schomburg</name>
</author>
<author><name sortKey="Buentzel, Jens" sort="Buentzel, Jens" uniqKey="Buentzel J" first="Jens" last="Buentzel">Jens Buentzel</name>
</author>
<author><name sortKey="Kisters, Klaus" sort="Kisters, Klaus" uniqKey="Kisters K" first="Klaus" last="Kisters">Klaus Kisters</name>
</author>
<author><name sortKey="Muecke, Ralph" sort="Muecke, Ralph" uniqKey="Muecke R" first="Ralph" last="Muecke">Ralph Muecke</name>
</author>
</analytic>
<series><title level="j">Molecules (Basel, Switzerland)</title>
<idno type="eISSN">1420-3049</idno>
<imprint><date when="2009" type="published">2009</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Cytoprotection</term>
<term>Humans</term>
<term>Lymphedema (drug therapy)</term>
<term>Neoplasms (drug therapy)</term>
<term>Neoplasms (prevention & control)</term>
<term>Radiation-Protective Agents (metabolism)</term>
<term>Radiation-Protective Agents (therapeutic use)</term>
<term>Randomized Controlled Trials as Topic</term>
<term>Selenium (chemistry)</term>
<term>Selenium (metabolism)</term>
<term>Selenium (therapeutic use)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Cytoprotection</term>
<term>Essais contrôlés randomisés comme sujet</term>
<term>Humains</term>
<term>Lymphoedème (traitement médicamenteux)</term>
<term>Radioprotecteurs (métabolisme)</term>
<term>Radioprotecteurs (usage thérapeutique)</term>
<term>Sélénium ()</term>
<term>Sélénium (métabolisme)</term>
<term>Sélénium (usage thérapeutique)</term>
<term>Tumeurs ()</term>
<term>Tumeurs (traitement médicamenteux)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="chemistry" xml:lang="en"><term>Selenium</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Radiation-Protective Agents</term>
<term>Selenium</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Lymphedema</term>
<term>Neoplasms</term>
</keywords>
<keywords scheme="MESH" qualifier="métabolisme" xml:lang="fr"><term>Radioprotecteurs</term>
<term>Sélénium</term>
</keywords>
<keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Neoplasms</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Radiation-Protective Agents</term>
<term>Selenium</term>
</keywords>
<keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Lymphoedème</term>
<term>Tumeurs</term>
</keywords>
<keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Radioprotecteurs</term>
<term>Sélénium</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Cytoprotection</term>
<term>Humans</term>
<term>Randomized Controlled Trials as Topic</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Cytoprotection</term>
<term>Essais contrôlés randomisés comme sujet</term>
<term>Humains</term>
<term>Sélénium</term>
<term>Tumeurs</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">The essential trace element selenium, which is a crucial cofactor in the most important endogenous antioxidative systems of the human body, is attracting more and more the attention of both laypersons and expert groups. The interest of oncologists mainly focuses in the following clinical aspects: radioprotection of normal tissues, radiosensitizing in malignant tumors, antiedematous effect, prognostic impact of selenium, and effects in primary and secondary cancer prevention. Selenium is a constituent of the small group of selenocysteine-containing selenoproteins and elicits important structural and enzymatic functions. Selenium deficiency has been linked to increased infection risk and adverse mood states. It has been shown to possess cancer-preventive and cytoprotective activities in both animal models and humans. It is well established that Se has a key role in redox regulation and antioxidant function, and hence in membrane integrity, energy metabolism and protection against DNA damage. Recent clinical trials have shown the importance of selenium in clinical oncology. Our own clinical study involving 48 patients suggest that selenium has a positive effect on radiation-associated secondary lymphedema in patients with limb edemas, as well as in the head and neck region, including endolaryngeal edema. Another randomized phase III study of our group was performed to examine the cytoprotective properties of selenium in radiation oncology. The aim was to evaluate whether sodium selenite is able to compensate a preexisting selenium deficiency and to prevent radiation induced diarrhea in adjuvant radiotherapy for pelvic gynecologic malignancies. Through this study, the significant benefits of sodium selenite supplementation with regards to selenium deficiency and radiotherapy induced diarrhea in patients with cervical and uterine cancer has been shown for the first time in a prospective randomized trial. Survival data imply that supplementation with selenium does not interfere with the positive biological effects of radiation treatment and might constitute a valuable adjuvant therapy option especially in marginally supplied individuals. More recently there were emerging concerns coming up from two large clinical prevention trials (NPC, SELECT), that selenium increases the possible risk of developing diabetes type II. Despite obvious flaws of both studies and good counterarguments, a controversial debate remains on the possible advantage and risks of selenium in cancer prevention. However, in the light of the recent clinical trials the potential benefits of selenium supplementation in tumor patients are undeniable, even if further research is needed.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">19924043</PMID>
<DateCreated><Year>2009</Year>
<Month>11</Month>
<Day>20</Day>
</DateCreated>
<DateCompleted><Year>2010</Year>
<Month>02</Month>
<Day>22</Day>
</DateCompleted>
<DateRevised><Year>2013</Year>
<Month>11</Month>
<Day>21</Day>
</DateRevised>
<Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1420-3049</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>14</Volume>
<Issue>10</Issue>
<PubDate><Year>2009</Year>
<Month>Oct</Month>
<Day>12</Day>
</PubDate>
</JournalIssue>
<Title>Molecules (Basel, Switzerland)</Title>
<ISOAbbreviation>Molecules</ISOAbbreviation>
</Journal>
<ArticleTitle>Selenium in oncology: from chemistry to clinics.</ArticleTitle>
<Pagination><MedlinePgn>3975-88</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.3390/molecules14103975</ELocationID>
<Abstract><AbstractText>The essential trace element selenium, which is a crucial cofactor in the most important endogenous antioxidative systems of the human body, is attracting more and more the attention of both laypersons and expert groups. The interest of oncologists mainly focuses in the following clinical aspects: radioprotection of normal tissues, radiosensitizing in malignant tumors, antiedematous effect, prognostic impact of selenium, and effects in primary and secondary cancer prevention. Selenium is a constituent of the small group of selenocysteine-containing selenoproteins and elicits important structural and enzymatic functions. Selenium deficiency has been linked to increased infection risk and adverse mood states. It has been shown to possess cancer-preventive and cytoprotective activities in both animal models and humans. It is well established that Se has a key role in redox regulation and antioxidant function, and hence in membrane integrity, energy metabolism and protection against DNA damage. Recent clinical trials have shown the importance of selenium in clinical oncology. Our own clinical study involving 48 patients suggest that selenium has a positive effect on radiation-associated secondary lymphedema in patients with limb edemas, as well as in the head and neck region, including endolaryngeal edema. Another randomized phase III study of our group was performed to examine the cytoprotective properties of selenium in radiation oncology. The aim was to evaluate whether sodium selenite is able to compensate a preexisting selenium deficiency and to prevent radiation induced diarrhea in adjuvant radiotherapy for pelvic gynecologic malignancies. Through this study, the significant benefits of sodium selenite supplementation with regards to selenium deficiency and radiotherapy induced diarrhea in patients with cervical and uterine cancer has been shown for the first time in a prospective randomized trial. Survival data imply that supplementation with selenium does not interfere with the positive biological effects of radiation treatment and might constitute a valuable adjuvant therapy option especially in marginally supplied individuals. More recently there were emerging concerns coming up from two large clinical prevention trials (NPC, SELECT), that selenium increases the possible risk of developing diabetes type II. Despite obvious flaws of both studies and good counterarguments, a controversial debate remains on the possible advantage and risks of selenium in cancer prevention. However, in the light of the recent clinical trials the potential benefits of selenium supplementation in tumor patients are undeniable, even if further research is needed.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Micke</LastName>
<ForeName>Oliver</ForeName>
<Initials>O</Initials>
<AffiliationInfo><Affiliation>Department of Radiotherapy and Radiation Oncology, Franziskus Hospital, Kiskerstrasse 26, D- 33615 Bielefeld, Germany.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Schomburg</LastName>
<ForeName>Lutz</ForeName>
<Initials>L</Initials>
</Author>
<Author ValidYN="Y"><LastName>Buentzel</LastName>
<ForeName>Jens</ForeName>
<Initials>J</Initials>
</Author>
<Author ValidYN="Y"><LastName>Kisters</LastName>
<ForeName>Klaus</ForeName>
<Initials>K</Initials>
</Author>
<Author ValidYN="Y"><LastName>Muecke</LastName>
<ForeName>Ralph</ForeName>
<Initials>R</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D016454">Review</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2009</Year>
<Month>10</Month>
<Day>12</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>Switzerland</Country>
<MedlineTA>Molecules</MedlineTA>
<NlmUniqueID>100964009</NlmUniqueID>
<ISSNLinking>1420-3049</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D011837">Radiation-Protective Agents</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>H6241UJ22B</RegistryNumber>
<NameOfSubstance UI="D012643">Selenium</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D019610" MajorTopicYN="N">Cytoprotection</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008209" MajorTopicYN="N">Lymphedema</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D009369" MajorTopicYN="N">Neoplasms</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
<QualifierName UI="Q000517" MajorTopicYN="N">prevention & control</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D011837" MajorTopicYN="N">Radiation-Protective Agents</DescriptorName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D016032" MajorTopicYN="N">Randomized Controlled Trials as Topic</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D012643" MajorTopicYN="N">Selenium</DescriptorName>
<QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
<QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
</MeshHeading>
</MeshHeadingList>
<NumberOfReferences>62</NumberOfReferences>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="received"><Year>2009</Year>
<Month>08</Month>
<Day>11</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="revised"><Year>2009</Year>
<Month>09</Month>
<Day>26</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted"><Year>2009</Year>
<Month>09</Month>
<Day>30</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2009</Year>
<Month>11</Month>
<Day>20</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2009</Year>
<Month>11</Month>
<Day>20</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2010</Year>
<Month>2</Month>
<Day>23</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>epublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">19924043</ArticleId>
<ArticleId IdType="pii">14103975</ArticleId>
<ArticleId IdType="doi">10.3390/molecules14103975</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
<affiliations><list><country><li>Allemagne</li>
</country>
</list>
<tree><noCountry><name sortKey="Buentzel, Jens" sort="Buentzel, Jens" uniqKey="Buentzel J" first="Jens" last="Buentzel">Jens Buentzel</name>
<name sortKey="Kisters, Klaus" sort="Kisters, Klaus" uniqKey="Kisters K" first="Klaus" last="Kisters">Klaus Kisters</name>
<name sortKey="Muecke, Ralph" sort="Muecke, Ralph" uniqKey="Muecke R" first="Ralph" last="Muecke">Ralph Muecke</name>
<name sortKey="Schomburg, Lutz" sort="Schomburg, Lutz" uniqKey="Schomburg L" first="Lutz" last="Schomburg">Lutz Schomburg</name>
</noCountry>
<country name="Allemagne"><noRegion><name sortKey="Micke, Oliver" sort="Micke, Oliver" uniqKey="Micke O" first="Oliver" last="Micke">Oliver Micke</name>
</noRegion>
</country>
</tree>
</affiliations>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/PubMed/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002A99 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 002A99 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Sante |area= LymphedemaV1 |flux= PubMed |étape= Checkpoint |type= RBID |clé= pubmed:19924043 |texte= Selenium in oncology: from chemistry to clinics. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i -Sk "pubmed:19924043" \ | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd \ | NlmPubMed2Wicri -a LymphedemaV1
![]() | This area was generated with Dilib version V0.6.31. | ![]() |